News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Change in the number of shares and votes in PledPharma

November 30, 2020

The number of shares and votes in PledPharma AB (publ) (“PledPharma” or the “Company”) has increased during the month of November due to the acquisition of Rare Thyroid Therapeutics International AB (RTT) with a purchase price consisting of, amongst others, 63,773,345 newly issued shares and after the exercise of the overallotment option as a consequence of the oversubscribed rights issue.

The press releases regarding the directed issue of shares and the overallotment were published on 5 October, 28 October, 3 November, and 25 November 2020. A total of 73,297,154 shares and votes have been added.
At 30 November 2020, which is the last trading day in November, the number of shares and votes in the Company amounts to 126,830,475.
The shares in the rights issue as the Company announced about on 5 October, 28 October and 25 November 2020 will be registered with the Swedish Companies Registration Office in December 2020.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10